{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:11:35Z","timestamp":1779387095269,"version":"3.53.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Glioblastoma is an aggressive astrocytic neoplasm characterized by significant intratumoral heterogeneity and resistance to standard therapies. Despite advances such as the Stupp protocol, the prognosis remains poor, with a median survival of 12\u201315 months. Mast cells in the tumor microenvironment (TME) release pro-inflammatory mediators, promoting tumor progression and therapeutic resistance. The Mas-related G protein-coupled receptor X2 (MRGPRX2), expressed on mast cells, is implicated in neuroinflammatory regulation. This study evaluates hydroxychloroquine (HCQ), a 4-aminoquinoline derivative, as a potential MRGPRX2 inhibitor using a comprehensive multidisciplinary approach. Density Functional Theory (DFT) at the B3LYP\/6\u201331\u2009+\u2009G(d,p) level was employed to analyze the structural and electronic properties of HCQ, validated by FTIR and Raman spectroscopy. To ensure statistical robustness and address receptor specificity, 100 independent blind docking simulations were performed using the high-resolution MRGPRX2 structure (PDB ID: 7S8L). The docking protocol was rigorously validated through a cross-docking study using the 7S8N reference ligand, yielding a high spatial consensus with an RMSD of 3.06 \u00c5. The results revealed that HCQ possesses a superior binding affinity of \u22127.0 kcal\/mol, while comparative docking with the standard therapeutic Temozolomide (TMZ) yielded a lower affinity of \u22125.6 kcal\/mol. Detailed residue-level analysis highlighted a distinct binding fingerprint for HCQ, involving specific interactions with residues such as Tyr137, Ser130, and Phe64, which were notably different from the TMZ-receptor complex. ADMET profiling confirmed HCQ\u2019s favorable pharmacokinetic properties and its potential to cross the blood-brain barrier.\n                    <jats:italic>In vitro<\/jats:italic>\n                    validation on U87-MG glioblastoma cells demonstrated a time-dependent cytotoxic effect, where HCQ significantly reduced cell viability to approximately 70% at 72 hours (p\u2009&lt;\u20090.01). This biological activity directly correlates with the strong binding profile and high affinity observed in the 100-run docking analysis\n                    <jats:bold>.<\/jats:bold>\n                    Our findings suggest that HCQ is predicted to interact with MRGPRX2 with a high binding affinity, supporting further functional validation and providing a novel structural basis for targeting mast cell-mediated neuroinflammation in glioblastoma treatment. These results advocate for the repositioning of HCQ as a targeted adjuvant therapy to overcome conventional treatment limitations.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0347956","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:32:53Z","timestamp":1779384773000},"page":"e0347956","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-9150","authenticated-orcid":true,"given":"Aliye Demet","family":"Demirag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmi Atil","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5862","authenticated-orcid":true,"given":"Gizem","family":"Akman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"8","key":"pone.0347956.ref001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"DN Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"pone.0347956.ref002","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"M Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"pone.0347956.ref003","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"PJ Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pone.0347956.ref004","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"Z An","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"pone.0347956.ref005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"RGW Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"7216","key":"pone.0347956.ref006","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"The Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"issue":"2","key":"pone.0347956.ref007","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"CW Brennan","year":"2013","journal-title":"Cell"},{"issue":"6","key":"pone.0347956.ref008","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnen\/59.6.539","article-title":"Loss of heterozygosity on chromosome 19 in secondary glioblastomas","volume":"59","author":"M Nakamura","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"pone.0347956.ref009","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"ME Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0347956.ref010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-013-1141-6","article-title":"Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss","volume":"126","author":"H Arita","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"10","key":"pone.0347956.ref011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"R Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0347956.ref012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/era.12.37","article-title":"Molecular mechanisms of temozolomide resistance in glioblastoma multiforme","volume":"12","author":"T-CA Johannessen","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7015","key":"pone.0347956.ref013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"SK Singh","year":"2004","journal-title":"Nature"},{"issue":"6190","key":"pone.0347956.ref014","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"AP Patel","year":"2014","journal-title":"Science"},{"issue":"1","key":"pone.0347956.ref015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"CD Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pone.0347956.ref016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"D Hambardzumyan","year":"2016","journal-title":"Nat Neurosci"},{"key":"pone.0347956.ref017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcell.2017.00043","article-title":"Metabolic Reprogramming in Glioma","volume":"5","author":"M Strickland","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"pone.0347956.ref018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1476-4598-9-135","article-title":"Survival signalling and apoptosis resistance in glioblastomas: Opportunities for targeted therapeutics","volume":"9","author":"C Krakstad","year":"2010","journal-title":"Mol Cancer"},{"issue":"7","key":"pone.0347956.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"F Klemm","year":"2020","journal-title":"Cell"},{"issue":"3","key":"pone.0347956.ref020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"H Subramanian","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"7542","key":"pone.0347956.ref021","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"BD McNeil","year":"2015","journal-title":"Nature"},{"issue":"16","key":"pone.0347956.ref022","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89362","article-title":"Dual action of neurokinin-1 antagonists on Mas-related GPCRs","volume":"1","author":"E Azimi","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"pone.0347956.ref023","article-title":"Chloroquine and hydroxychloroquine for cancer therapy","volume":"1","author":"G Manic","year":"2014","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"pone.0347956.ref024","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1083\/jcb.90.3.665","article-title":"Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages","volume":"90","author":"B Poole","year":"1981","journal-title":"J Cell Biol"},{"issue":"19","key":"pone.0347956.ref025","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108863","article-title":"Autophagy in major human diseases","volume":"40","author":"DJ Klionsky","year":"2021","journal-title":"EMBO J"},{"issue":"6","key":"pone.0347956.ref026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","article-title":"Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes","volume":"45","author":"C-H Jang","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"pone.0347956.ref027","first-page":"1833","article-title":"Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a novel mechanism involving inhibition of ERK1\/2","volume":"66","author":"SM Weber","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"pone.0347956.ref028","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"A Kuznik","year":"2011","journal-title":"J Immunol"},{"key":"pone.0347956.ref029","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRev.136.B864","article-title":"Inhomogeneous electron gas","volume":"136","author":"P Hohenberg","year":"1964","journal-title":"Phys Rev"},{"issue":"2","key":"pone.0347956.ref030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1063\/1.449486","article-title":"Natural population analysis","volume":"83","author":"AE Reed","year":"1985","journal-title":"J Chem Phys"},{"issue":"2","key":"pone.0347956.ref031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wcms.19","article-title":"The electrostatic potential: An overview","volume":"1","author":"JS Murray","year":"2011","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"pone.0347956.ref032","volume-title":"Molecular vibrations: The theory of infrared and Raman vibrational spectra","author":"EB Wilson","year":"1955"},{"issue":"16","key":"pone.0347956.ref033","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"GM Morris","year":"2009","journal-title":"J Comput Chem"},{"issue":"1","key":"pone.0347956.ref034","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"K Mukai","year":"2018","journal-title":"Immunol Rev"},{"issue":"9","key":"pone.0347956.ref035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"JMM Levy","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"pone.0347956.ref036","volume-title":"Gaussian 09, Revision D.01","author":"MJ Frisch","year":"2013"},{"issue":"7","key":"pone.0347956.ref037","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1063\/1.464913","article-title":"Density\u2010functional thermochemistry. III. The role of exact exchange","volume":"98","author":"AD Becke","year":"1993","journal-title":"J Chem Phys"},{"key":"pone.0347956.ref038","volume-title":"Exploring chemistry with electronic structure methods","author":"JB Foresman","year":"1996"},{"key":"pone.0347956.ref039","volume-title":"Molecular Vibrations: The Theory of Infrared and Raman Vibrational Spectra","author":"EB Wilson","year":"1955"},{"issue":"10","key":"pone.0347956.ref040","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/ja00504a009","article-title":"Systematic ab initio gradient calculation of molecular geometries, force constants, and dipole moment derivatives","volume":"101","author":"P Pulay","year":"1979","journal-title":"J Am Chem Soc"},{"issue":"41","key":"pone.0347956.ref041","doi-asserted-by":"crossref","first-page":"16502","DOI":"10.1021\/jp960976r","article-title":"Harmonic vibrational frequencies: an evaluation of Hartree\u2212Fock, M\u00f8ller\u2212Plesset, quadratic configuration interaction, density functional theory, and semiempirical scale factors","volume":"100","author":"AP Scott","year":"1996","journal-title":"J Phys Chem"},{"issue":"2","key":"pone.0347956.ref042","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"O Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"5","key":"pone.0347956.ref043","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"S Forli","year":"2016","journal-title":"Nat Protoc"},{"issue":"3","key":"pone.0347956.ref044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.19113\/sdufenbed.871423","article-title":"Molecular docking analysis of used drugs for the treatment of cancer","volume":"25","author":"AD Demirag","year":"2021","journal-title":"S\u00fcleyman Demirel \u00dcniversitesi Fen Bilimleri Enstit\u00fcs\u00fc Dergisi"},{"issue":"1","key":"pone.0347956.ref045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.56171\/ojn.1109606","article-title":"Computational investigation of the interaction mechanism of some anti-alzheimer drugs with the acetylcholinesterase enzyme","volume":"8","author":"S \u00c7el\u00efk","year":"2023","journal-title":"Open Journal of Nano"},{"issue":"3","key":"pone.0347956.ref046","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","article-title":"Prediction of drug solubility from structure","volume":"54","author":"WL Jorgensen","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"pone.0347956.ref047","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"A Daina","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0347956.ref048","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"CA Lipinski","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"pone.0347956.ref049","doi-asserted-by":"crossref","DOI":"10.1002\/0470011149","volume-title":"Infrared spectroscopy: fundamentals and applications","author":"BH Stuart","year":"2004"},{"key":"pone.0347956.ref050","doi-asserted-by":"crossref","DOI":"10.1002\/9781119440598","volume-title":"Modern Raman Spectroscopy: A Practical Approach","author":"E Smith","year":"2019"},{"key":"pone.0347956.ref051","unstructured":"GraphPad Prism version 6.00. La Jolla, CA: GraphPad Software. 2012."},{"issue":"8","key":"pone.0347956.ref052","article-title":"Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin","volume":"6","author":"GW Ejuh","year":"2020","journal-title":"Heliyon"},{"key":"pone.0347956.ref053","first-page":"133381","article-title":"Quantum chemical study of hydroxychloroquine and chloroquine","volume":"1265","author":"N Chafai","year":"2022","journal-title":"J Mol Struct"},{"issue":"4","key":"pone.0347956.ref054","first-page":"045011","article-title":"First-principles DFT investigations of the vibrational spectra of chloroquine and hydroxychloroquine","volume":"5","author":"XY Liu","year":"2021","journal-title":"J Phys Commun"},{"issue":"8","key":"pone.0347956.ref055","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/auto.28984","article-title":"A phase I\/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme","volume":"10","author":"MR Rosenfeld","year":"2014","journal-title":"Autophagy"},{"issue":"3","key":"pone.0347956.ref056","first-page":"505","article-title":"Phase II study of chloroquine and hydroxychloroquine in glioblastoma patients","volume":"152","author":"AH Compter","year":"2021","journal-title":"J Neurooncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:33:04Z","timestamp":1779384784000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347956"}},"subtitle":[],"editor":[{"given":"Saki","family":"Raheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347956","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}